HIRONOBU HAMADA

Last Updated :2022/12/02

Affiliations, Positions
Graduate School of Biomedical and Health Sciences(Health Sciences), Professor
E-mail
hirohamadahiroshima-u.ac.jp
Self-introduction
I performed basic and clinical researches for refractory pulmonary diseases such as interstitial pneumonia and lung cancer. In addition, I performed clinical researches for pulmonary rehabilitation collaborated with several hospitals.

Basic Information

Academic Degrees

  • Doctor of Philosophy in Medical Science, Ehime University

Educational Activity

  • [Bachelor Degree Program] School of Medicine : Program of Health Sciences : Physical Therapy
  • [Master's Program] Graduate School of Biomedical and Health Sciences : Division of Integrated Health Sciences : Program of Health Sciences
  • [Doctoral Program] Graduate School of Biomedical and Health Sciences : Division of Integrated Health Sciences : Program of Health Sciences

Research Fields

  • Complex systems;Biomedical engineering;Rehabilitation science / Welfare engineering

Educational Activity

Course in Charge

  1. 2022, Undergraduate Education, Intensive, Practice of Medicine I
  2. 2022, Undergraduate Education, Intensive, Practice of Medicine II
  3. 2022, Undergraduate Education, Second Semester, Graduation Theses
  4. 2022, Undergraduate Education, First Semester, Internal medicine Ⅰ
  5. 2022, Undergraduate Education, Second Semester, Internal medicine II
  6. 2022, Undergraduate Education, First Semester, Rehabilitation for internal disorders
  7. 2022, Undergraduate Education, Second Semester, Practice in rehabilitation for internal disorders
  8. 2022, Undergraduate Education, 2Term, Introduction to Rehabilitation Science
  9. 2022, Undergraduate Education, 2Term, Introduction to Rehabilitation Science
  10. 2022, Undergraduate Education, 1Term, Sports Medicine
  11. 2022, Undergraduate Education, First Semester, Internal medicine Ⅰ
  12. 2022, Undergraduate Education, Second Semester, Internal medicine II
  13. 2022, Undergraduate Education, First Semester, Rehabilitation for internal disorders
  14. 2022, Graduate Education (Doctoral Program) , Year, Advanced Research on Development of Physical Therapy and Occupational Therapy Sciences
  15. 2022, Graduate Education (Master's Program) , 1Term, Advanced Lecture on Preventive Medicine for Evidence-based Health Guidance A
  16. 2022, Graduate Education (Master's Program) , First Semester, Advanced Lecture on Health Science Ⅲ(Experiment Research)
  17. 2022, Graduate Education (Master's Program) , First Semester, Advanced Lecture on Health Science Ⅲ(Experiment Research)
  18. 2022, Graduate Education (Doctoral Program) , First Semester, Advanced Research on Development of Physical Therapy and Occupational Therapy Sciences
  19. 2022, Graduate Education (Doctoral Program) , Second Semester, Advanced Research on Development of Physical Therapy and Occupational Therapy Sciences
  20. 2022, Graduate Education (Master's Program) , First Semester, Lecture on Physical Analysis and Therapeutic Sciences
  21. 2022, Graduate Education (Master's Program) , First Semester, Lecture on Physical Analysis and Therapeutic Sciences
  22. 2022, Graduate Education (Master's Program) , First Semester, Seminar on Physical Analysis and Therapeutic Sciences
  23. 2022, Graduate Education (Master's Program) , Second Semester, Seminar on Physical Analysis and Therapeutic Sciences
  24. 2022, Graduate Education (Master's Program) , First Semester, Seminar on Physical Analysis and Therapeutic Sciences
  25. 2022, Graduate Education (Master's Program) , Second Semester, Seminar on Physical Analysis and Therapeutic Sciences
  26. 2022, Graduate Education (Master's Program) , Year, Research on Physical Analysis and Therapeutic Sciences
  27. 2022, Graduate Education (Doctoral Program) , First Semester, Advanced Lecture on Physical Analysis and Therapeutic Sciences
  28. 2022, Graduate Education (Doctoral Program) , First Semester, Advanced Lecture on Physical Analysis and Therapeutic Sciences
  29. 2022, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Physical Analysis and Therapeutic Sciences
  30. 2022, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Physical Analysis and Therapeutic Sciences
  31. 2022, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Physical Analysis and Therapeutic Sciences
  32. 2022, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Physical Analysis and Therapeutic Sciences

Research Activities

Academic Papers

  1. Effects of soy protein isolate and soy peptide preload on gastric emptying rate and postprandial glycemic control in healthy humans, JOURNAL OF PHYSIOLOGICAL ANTHROPOLOGY, 41(1), 20220627
  2. Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer, CANCER SCIENCE, 112(1), 369-379, 202101
  3. Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma, CLINICAL RESPIRATORY JOURNAL, 15(1), 48-55, 202101
  4. Concomitant emphysema might increase the false-negative rate of urinary antigen tests in patients with pneumococcal pneumonia: results from a retrospective study, EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 40(4), 871-877, 202104
  5. Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer, ANTICANCER RESEARCH, 41(3), 1497-1506, 202103
  6. Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone, ANTICANCER RESEARCH, 41(5), 2661-2667, 202105
  7. Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients, SCIENTIFIC REPORTS, 11(1), 20210512
  8. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study, PULMONARY PHARMACOLOGY & THERAPEUTICS, 67, 202104
  9. A machine-learning based approach to quantify fine crackles in the diagnosis of interstitial pneumonia A proof-of-concept study, MEDICINE, 100(7), 20210219
  10. IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis, PLOS ONE, 16(6), 20210604
  11. Quantitative parameters of lymphocyte nuclear morphology in bronchoalveolar lavage fluid as novel biomarkers for sarcoidosis, ORPHANET JOURNAL OF RARE DISEASES, 16(1), 20210703
  12. Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity, STEM CELL RESEARCH & THERAPY, 12(1), 20210823
  13. Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis, STEM CELL RESEARCH & THERAPY, 12(1), 20210916
  14. Analysis of microRNA Expression in Liquid-Based Cytology Samples May Be Useful for Primary Lung Cancer Diagnosis, AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 156(4), 644-652, 202110
  15. Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 88(5), 857-865, 202111
  16. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25(1), 74-81, 202001
  17. Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer, JOURNAL OF THORACIC DISEASE, 12(3), 1079-1084, 202003
  18. Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, RESPIROLOGY, 25(3), 275-280, 202003
  19. Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, RESPIRATORY RESEARCH, 21(1), 20200611
  20. Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease, RESPIRATORY MEDICINE, 172, 202010
  21. Extent of pulmonary fibrosis on high-resolution computed tomography is a prognostic factor in patients with pleuroparenchymal fibroelastosis, RESPIRATORY INVESTIGATION, 58(6), 465-472, 202011
  22. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers, JAMA NETWORK OPEN, 3(11), 20201112
  23. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1, CANCER LETTERS, 442, 31-39, 2019
  24. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery, MEDICINE, 98(5), 201902
  25. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma A case report, MEDICINE, 98(12), 201903
  26. L-cysteine improves blood fluidity impaired by acetaldehyde: In vitro evaluation, PLOS ONE, 14(3), 20190329
  27. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts, JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 23(4), 2984-2994, 201904
  28. Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients, INTERNAL MEDICINE, 58(7), 915-920, 2019
  29. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress, FREE RADICAL BIOLOGY AND MEDICINE, 136, 52-59, 20190520
  30. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia, RESPIRATORY MEDICINE, 152, 44-50, 201906
  31. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, RESPIRATORY INVESTIGATION, 57(5), 451-459, 201909
  32. C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis, RESPIRATION, 98(3), 212-220, 201909
  33. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer, ANTICANCER RESEARCH, 39(10), 5725-5731, 201910
  34. Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis, INTERNAL MEDICINE, 58(21), 3129-3132, 2019
  35. Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study, JOURNAL OF CLINICAL MEDICINE, 8(12), 201912
  36. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 81(1), 131-139, 201801
  37. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma, LUNG CANCER, 119, 21-24, 201805
  38. Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma, EUROPEAN RESPIRATORY JOURNAL, 51(5), 20180501
  39. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study, IN VIVO, 32(5), 1155-1160, 2018
  40. Use of proton pump inhibitors is associated with increased mortality due to nosocomial pneumonia in bedridden patients receiving tube feeding, GERIATRICS & GERONTOLOGY INTERNATIONAL, 18(8), 1215-1218, 201808
  41. Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice, MOLECULAR THERAPY-NUCLEIC ACIDS, 12, 698-706, 20180907
  42. Plasminogen activator inhibitor-1 serves an important role in radiation-induced pulmonary fibrosis, EXPERIMENTAL AND THERAPEUTIC MEDICINE, 16(4), 3070-3076, 201810
  43. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study, MOLECULAR AND CLINICAL ONCOLOGY, 9(5), 539-544, 201811
  44. Effects of Hochuekkito combined with pulmonary rehabilitation in patients with chronic obstructive pulmonary disease, EXPERIMENTAL AND THERAPEUTIC MEDICINE, 16(6), 5236-5242, 201812
  45. Posture and firmness changes in a pressure-relieving air mattress affect cough strength in elderly people with dysphagia, PLOS ONE, 13(12), 20181211
  46. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody A retrospective cohort study, MEDICINE, 97(49), 201812
  47. The effect of body weight support on predicted locomotive physical activity, The Journal of Physical Therapy Science, 30, 759-763, 2018
  48. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis, RESPIRATORY MEDICINE, 123, 105-109, 201702
  49. MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study, BMC CANCER, 17, 20170412
  50. Central command increases muscular oxygenation of the non-exercising arm at the early period of voluntary one-armed cranking, PHYSIOLOGICAL REPORTS, 5(7), 201704
  51. Suplatast tosilate protects the lung against hyperoxic lung injury by scavenging hydroxyl radicals, FREE RADICAL BIOLOGY AND MEDICINE, 106, 1-9, 201705
  52. AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis, RESPIROLOGY, 22(5), 965-971, 201707
  53. Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets, BMC MEDICAL GENETICS, 18, 20170818
  54. CLINICAL AND MOLECULAR FEATURES OF RAPIDLY PROGRESSIVE CHRONIC HYPERSENSITIVITY PNEUMONITIS, SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 34(1), 48-57, 2017
  55. Oxidative stress in cigarette smokers and patients with chronic obstructive pulmonary disease, Oxidants and Antioxidants in Medical Science, 6, 19-24, 2017
  56. Chronic Intestinal Pseudo-obstruction and Orthostatic Hypotension Associated with Small Cell Lung Cancer that Improved with Tumor Reduction after Chemoradiotherapy, INTERNAL MEDICINE, 56(19), 2627-2631, 2017
  57. AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma, ONCOTARGET, 8(55), 94382-94392, 20171107
  58. Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis, INTERNAL MEDICINE, 56(24), 3327-3331, 2017
  59. Effect of Different Levels of Pressure Relieving Air-Mattress Firmness on Cough Strength, PLOS ONE, 11(1), 20160107
  60. Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-beta-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts, PLOS ONE, 11(2), 20160209
  61. Cardiac parasympathetic outflow during dynamic exercise in humans estimated from power spectral analysis of P-P interval variability, EXPERIMENTAL PHYSIOLOGY, 101(3), 397-409, 20160301
  62. The effect of exercise on blood fluidity: Use of the capillary model to assess the clogginess of blood, CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 61(4), 559-569, 2016
  63. Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis, DISEASE MARKERS, 2016
  64. Long-term pulmonary complications of chemical weapons exposure in former poison gas factory workers, INHALATION TOXICOLOGY, 28(8), 343-348, 201607
  65. Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma, CANCER RESEARCH, 76(11), 3285-3294, 20160601
  66. Oxidative stress induced by smoking and exercise., International Journal of Medical and Biological Frontiers, 22, 203-213, 2016
  67. Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients, DRUG DESIGN DEVELOPMENT AND THERAPY, 8, 1211-1219, 2014
  68. Phase II trial of S-1 as third-line or further chemotherapy in patients with advanced non-small-cell lung cancer, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 19(6), 1005-1010, 201412
  69. Phase-dependent modulation of corticospinal excitability during the observation of the initial phase of gait, SOMATOSENSORY AND MOTOR RESEARCH, 31(4), 209-213, 201412
  70. Cigarette smoking does not induce plasma or pulmonary oxidative stress after moderate-intensity exercise., JOURNAL OF PHYSICAL THERAPY SCIENCE, 26, 413-415, 2014
  71. Differential contribution of ACh-muscarinic and b-adrenergic receptors to vasodilatation in noncontracting muscle during voluntary one-legged excercise., PHYSIOLOGICAL REPORTS, 2, e12202, 2014
  72. Characteristics of Patients with Severe Heart Failure Exhibiting Exercise Oscillatory Ventilation, CLINICAL AND EXPERIMENTAL HYPERTENSION, 35(4), 267-272, 2013
  73. Evidence for centrally-induced cholinergic vasodilatation in skeletal muscle during voluntary one-legged cycling and motor imagery in humans, PHYSIOLOGICAL REPORTS, 1(4), 20130901
  74. EGCG induces human mesothelioma cell death by inducing reactive oxygen species and autophagy, CANCER CELL INTERNATIONAL, 13, 20130223
  75. Plasma oxidative stress is induced by single-sprint anaerobic exercise in young cigarette smokers, CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING, 33(3), 241-244, 201305
  76. Usefulness of a selective neutrophil elastase inhibitor, sivelestat, in acute lung injury patients with sepsis, DRUG DESIGN DEVELOPMENT AND THERAPY, 7, 305-316, 2013
  77. Pulmonary Oxidative Stress Is Induced by Maximal Exercise in Young Cigarette Smokers, NICOTINE & TOBACCO RESEARCH, 14(2), 243-247, 201202
  78. Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer, INTERNATIONAL JOURNAL OF CANCER, 130(2), 377-387, 20120115
  79. The evaluation of the internal quality control of respiratory function tests, 37(3), 287-292, 20120601
  80. Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo, INTERNATIONAL JOURNAL OF ONCOLOGY, 41(2), 449-456, 201208
  81. Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma, INTERNATIONAL JOURNAL OF ONCOLOGY, 41(5), 1610-1618, 201211
  82. Attenuation of the Muscle Metaboreflex in Patients with Type 2 Diabetes, JOURNAL OF PHYSICAL THERAPY SCIENCE, 24(8), 721-724, 201209
  83. Antitussive effect of bakumondoto a fixed kampo medicine (six herbal components) for treatment of post-infectious prolonged cough: Controlled clinical pilot study with 19 patients, PHYTOMEDICINE, 18(8-9), 630-633, 20110615
  84. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease, RESPIRATORY RESEARCH, 12, 20110726

Publications such as books

  1. 2013, Handbook on Reactive oxygen species (ROS): formation mechanisms, physiological roles and common harmful effects, Oxidative stress in lungs and blood induced by smoking and exercise, Nova Science Publishers, 2013, Scholarly Book, Joint work, Taito S, Hamada H
  2. 2014, Acute Lung Injury: Epidemiology, Health Effects and Therapeutic Treatment Strategies., Pharmacological therapies for acute respiratory distress syndrome., Nova Science Publishers, 2014, Scholarly Book, Single work, Hironobu Hamada

Social Activities

Organizing Academic Conferences, etc.

  1. 2017/10, 2017/10

History as Peer Reviews of Academic Papers

  1. 2021, Geriatrics and Gerontology International, 1